FDA grants Roche s Perjeta regimen Priority Review for use before surgery in HER2-positive early-stage breast cancer
|
|
- Natalie Stafford
- 7 years ago
- Views:
Transcription
1 Media Release Basel, 2 July, 2013 FDA grants Roche s Perjeta regimen Priority Review for use before surgery in HER2-positive early-stage breast cancer Application follows proposed new FDA pathway designed to help bring promising medicines to people with earlier stages of breast cancer faster Perjeta is one of the first medicines the FDA will evaluate as an option given before surgery (neoadjuvant treatment) Perjeta, in combination with Herceptin and chemotherapy, was approved by the FDA in 2012 for HER2- positive metastatic breast cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company s supplemental Biologics License Application (sbla) for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive earlystage breast cancer. The FDA has granted a Priority Review of the application and will make a decision on approval by October 31, The impact of treatment in breast cancer is greatest in the early stage, before the cancer has spread to other parts of the body, said Hal Barron, M.D., Roche s Chief Medical Officer and Head, Global Product Development. We look forward to working with the FDA to bring this potential option to people with HER2-positive early-stage breast cancer as soon as possible. Neoadjuvant therapy is a treatment option given after diagnosis but before surgery for early-stage breast cancer (cancer that has not spread beyond the breast or lymph nodes). Neoadjuvant treatment aims to reduce a tumour s size so it may be easier to surgically remove, or to allow for breast-conserving surgery. There are currently no FDA-approved neoadjuvant treatments for cancer. A common measure of neoadjuvant treatment effect in breast cancer is pathological complete response (pcr), which means there is no tumour F. Hoffmann-La Roche Ltd 4070 Basel Switzerland Group Communications Roche Group Media Relations Tel Fax /5
2 tissue detectable at the time of surgery. Perjeta is already approved in the U.S. and Europe for people with HER2-positive metastatic breast cancer, an advanced form of the disease. Perjeta is a personalised medicine that targets the HER2 receptor, a protein found in high quantities on the outside of cancer cells in HER2-positive cancers. The combination of Perjeta, Herceptin and docetaxel chemotherapy is thought to provide a more comprehensive blockade of HER signalling pathways. A Priority Review designation is granted to medicines that the FDA believes have the potential to provide significant improvements in the treatment, prevention or diagnosis of a disease. The application is based primarily on results from NEOSPHERE and TRYPHAENA, two Phase II studies of Perjeta in HER2-positive early-stage breast cancer, as well as on longer-term safety data from the Phase III CLEOPATRA study of Perjeta in HER2-positive metastatic breast cancer. About the NEOSPHERE Study The NEOSPHERE study (Neoadjuvant Study of Pertuzumab and Herceptin in an Early Regimen Evaluation) is a randomised, multicentre, international Phase II study that was conducted in 417 people with newly diagnosed HER2-positive, locally advanced, inflammatory or early-stage breast cancer. Participants were randomised to four study arms and received four cycles (12 weeks) of neoadjuvant treatment. The primary endpoint was pcr. Secondary endpoints included clinical response, time to clinical response, safety profile, disease-free survival (DFS), breast-conserving surgery rate and biomarker assessment. Study data showed the following: Treatment with Perjeta, Herceptin and docetaxel chemotherapy significantly improved the rate of pcr by 58 percent compared to Herceptin and docetaxel alone (45.8 percent vs percent, p=0.014). - pcr of 29.0 percent for Herceptin and docetaxel - pcr of 45.8 percent for Perjeta, Herceptin and docetaxel - pcr of 16.8 percent for Perjeta and Herceptin - pcr of 24.0 percent for Perjeta and docetaxel The combination of Perjeta, Herceptin and docetaxel was not associated with a significant increase in adverse events (AEs) or cardiac AEs, compared to Herceptin and docetaxel. The most common severe (Grade 3 or higher) AEs for the Perjeta regimen were neutropenia (decrease in a certain type of white blood cell, 44.9 percent), febrile neutropenia (fever associated with decrease in a certain type of white blood cell, 8.4 percent) and diarrhea (5.6 percent). 2/5
3 About the TRYPHAENA Study The TRYPHAENA study (ToleRabilitY of Pertuzumab, Herceptin and AnthracyclinEs in NeoAdjuvant breast cancer) is a randomized, multicenter Phase II study that was conducted in 225 people with HER2- positive locally advanced, inflammatory or early-stage breast cancer. Participants were randomised to one of three neoadjuvant Perjeta regimens. The primary endpoint was cardiac safety. Secondary endpoints included pcr, clinical response, breast-conserving surgery rate, DFS, progression-free survival (PFS), overall survival (OS) and biomarker assessment. Study data showed the following: The study was not powered to compare the three study arms. The rate of pcr in the three arms were as follows: - pcr of 61.6 percent for Perjeta, Herceptin and anthracycline-based chemotherapy, followed by Perjeta, Herceptin and docetaxel - pcr of 57.3 percent for anthracycline-based chemotherapy, followed by Perjeta, Herceptin and docetaxel - pcr of 66.2 percent for the anthracycline-free arm (Perjeta, Herceptin, docetaxel and carboplatin chemotherapy) No new or unexpected cardiac AEs, or other AEs, were observed in any of the study arms. AEs observed were consistent with those seen in previous studies of Perjeta, Herceptin and chemotherapy, either in combination or alone. The most common severe AEs in any of the three study arms were: - In the concurrent arm: neutropenia (47.2 percent), leukopenia (decrease in overall white blood cells, 19.4 percent) and febrile neutropenia (18.1 percent) - In the sequential arm: neutropenia (42.7 percent), leukopenia (12.0 percent) and febrile neutropenia (9.3 percent) - In the anthracycline-free arm: neutropenia (46.1 percent), febrile neutropenia (17.1 percent), anemia (decrease in red blood cells, 17.1 percent); the AEs of diarrhea, leukopenia, anemia and thrombocytopenia (decrease in platelets) all had an incidence of 11.8 percent. The ongoing Phase III APHINITY study will further evaluate Perjeta in the adjuvant setting (after surgery) and compares Perjeta, Herceptin and standard regimens of adjuvant chemotherapy with Herceptin and standard regimens of adjuvant chemotherapy in people with HER2-positive early-stage breast cancer. The study will enroll approximately 4,800 people, and the primary endpoint is invasive disease-free survival (IDFS). About Perjeta Perjeta is designed specifically to prevent the HER2 receptor from pairing (or dimerising ) with other HER receptors (EGFR/HER1, HER3 and HER4) on the surface of cells, a process that is believed to play a role in 3/5
4 tumour growth and survival. Binding of Perjeta to HER2 may also signal the body s immune system to destroy the cancer cells. The mechanisms of action of Perjeta and Herceptin are believed to complement each other, as both bind to the HER2 receptor, but to different places. About breast cancer Breast cancer is the most common cancer among women worldwide. Each year, about 1.4 million new cases of breast cancer are diagnosed worldwide, and over 450,000 women will die of the disease annually. In HER2-positive breast cancer, increased quantities of the human epidermal growth factor receptor 2 (HER2) are present on the surface of the tumour cells. This is known as HER2 positivity and affects approximately percent of women with breast cancer. HER2-positive cancer is a particularly aggressive form of breast cancer. About Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by law. Additional information Roche in Oncology: Roche Group Media Relations Phone: / basel.mediaoffice@roche.com - Alexander Klauser (Head) - Silvia Dobry 4/5
5 - Daniel Grotzky - Štěpán Kráčala 5/5
FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable
More informationRoche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy
Media Release Basel, 6 June 2012 Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced
More informationFDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema
Media Release Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First major treatment advance in more than 25 years for sight-threatening condition
More informationMedia Release. Basel, 27 September 2015
Media Release Basel, 27 September 2015 Two positive studies of Roche s investigational cancer immunotherapy atezolizumab in specific type of lung cancer presented at 2015 European Cancer Congress Phase
More informationMedia Release. Basel, 11 June 2009. RA patients with enhanced response identified
Media Release Basel, 11 June 2009 New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis RA patients
More informationRoche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA
Media Release Basel, 28 June 2016 Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA OCREVUS is the first investigational medicine
More informationBREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I
BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness
More informationWhat s New With HER2?
What s New With HER2? Trastuzumab emtansine and pertuzumab for metastatic breast cancer Lindsay Livingston Pharmacist CancerCare Manitoba October 3, 2014 Presenter Disclosure Faculty: Lindsay Livingston
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More information5.04.20. Perjeta. Perjeta (pertuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.20 Subject: Perjeta Page: 1 of 5 Last Review Date: June 19, 2015 Perjeta Description Perjeta (pertuzumab)
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationMedia Release. Basel, 8 October 2015
Media Release Basel, 8 October 2015 Roche s ocrelizumab first investigational medicine to show positive pivotal study results in both relapsing and primary progressive forms of multiple sclerosis Ocrelizumab
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationThe NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab.
Cost Effectiveness of Pertuzumab (Perjeta ) in Combination with Trastuzumab and Docetaxel in Adults with HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer Who Have Not Received Previous
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationNew Approval Mechanism for Breast Cancer using pathologic Complete Response
New Approval Mechanism for Breast Cancer using pathologic Complete Response Sandra M. Swain, MD, FACP Medical Director, Washington Cancer Institute MedStar Washington Hospital Center Professor of Medicine
More informationBreast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania
Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer Kevin R. Fox, MD University of Pennsylvania Prevention of Breast Cancer Accepted treatments Tamoxifen (premenopausal
More informationMetastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
More informationMiquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
More informationUnderstanding your pathology report
Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationRoche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from three Phase III studies of the
Media Release Basel, 12 April 2016 Roche to present new data at AAN showing superior efficacy of investigational medicine ocrelizumab versus comparators on disease activity and progression in two forms
More informationLOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT
LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of
More informationCancer patients waiting for potentially live-saving treatments in UK
Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.
More informationtrastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd
trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd 06 December 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationGilberto de Lima Lopes, MD, MBA, FAMS Chief Medical and Scientific Officer, Oncoclinicas Group Asst. Prof. of Oncology, Johns Hopkins University
Gilberto de Lima Lopes, MD, MBA, FAMS Chief Medical and Scientific Officer, Oncoclinicas Group Asst. Prof. of Oncology, Johns Hopkins University Assoc. Editor ASCO University and JGO Progress Against
More informationTrastuzumab (Herceptin ) for patients with metastatic breast cancer
JULY 2007 Incorporates published evidence to November 2006 INFORMATION ABOUT Trastuzumab (Herceptin ) for patients with metastatic breast cancer This information has been developed to help you understand
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationDecision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
More information91,747 employees in over 100 countries
Roche in Brief 2015 Roche Who we are Who we are Roche Who we are 91,747 employees in over 100 countries CHF 48.1 bn in Group sales in 2015 # 1 in biotech, oncology, in vitro diagnostics and hospital market
More informationREFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for HER2-Positive Breast Cancer in China Market
More informationRoche reports solid sales growth in the first quarter of 2016
Media Release Basel, 19 April 2016 Roche reports solid sales growth in the first quarter of 2016 Group sales up 4% 1 at constant exchange rates, 5% in Swiss francs Pharmaceuticals Division sales increase
More informationWhat is the optimal sequence of anti-her2 therapy in metastatic breast cancer?
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
More informationGastric Cancer. Brochure More information from http://www.researchandmarkets.com/reports/2228929/
Brochure More information from http://www.researchandmarkets.com/reports/2228929/ Gastric Cancer Description: Gastric cancer (GC) is one of the most common malignancies in terms of incidence and the second
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationDRUG NAME: Pertuzumab
DRUG NAME: Pertuzumab SYNONYM(S): COMMON TRADE NAME(S): PERJETA CLASSIFICATION: monoclonal antibody Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM
More informationcure to HER2-Positive Breast Cancer What Is HER2? Making the Diagnosis Treatment Strategies Side Effects of Therapy Tips From a Survivor And More
A Patient s Guide to HER2-Positive Breast Cancer What Is HER2? Making the Diagnosis Treatment Strategies Side Effects of Therapy Tips From a Survivor And More cure C a n c e r U p d a t e s, R e s e a
More informationWhat You Need to Know About Lung Cancer Immunotherapy
What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationMetastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY
More information12.5 VI.2 ELEMENTS FOR A PUBLIC SUMMARY
12.5 VI.2 ELEMENTS FOR A PUBLIC SUMMARY 12.5.1 VI.2.1 Overview of disease epidemiology Breast cancer affects 10 12% of women globally, and is more common among older people. Some cancer cells have proteins
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationASCO. R&D Supply Chain and Clinical Trials Supply Management A Life Sciences Solution. Award for the "Best Business Transformation project 2010
ASCO Award for the "Best Business Transformation project 2010 R&D Supply Chain and Clinical Trials Supply Management A Life Sciences Solution Geert Crauwels Partner Life Sciences Industry Lodestone Amelia
More informationBREAST CANCER PATHOLOGY
BREAST CANCER PATHOLOGY FACT SHEET Version 4, Aug 2013 This fact sheet was produced by Breast Cancer Network Australia with input from The Royal College of Pathologists of Australasia I m a nurse and know
More informationCLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD
CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationGuidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationHAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
More informationStrength of Study End Point(s): Progression-free survival
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Paclitaxel for the First-line Treatment of Metastatic Breast Cancer Drug/Drug Combination: Bevacizumab and
More informationHER2 Testing in Breast Cancer
HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor
More informationCLINICAL POLICY Department: Medical Management Document Name: HER2 Breast Cancer Treatments
Page: 1 of 11 Specialist Review: Revised: 06/13 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review
More informationCurriculum Vitae of Luca Gianni
Education: 1976: State University of Milan, Milan, Italy: Medical Doctor with honors 1981: State University of Milan, Milan, Italy: Board- Certified in Internal Medicine Brief Chronology of Activities
More informationREPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationInvasive lobular breast cancer
Invasive lobular breast cancer This booklet is about invasive lobular breast cancer. It describes what invasive lobular breast cancer is, the symptoms, how it s diagnosed and possible treatments. Diagnosed
More informationAppendix One. HER2-positive early breast cancer, its treatment and prognosis
Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf
More informationLife writes the questions We pursue the answers
Life writes the questions We pursue the answers Life writes the questions. 1 What will help me? Can I have hope? When will the others notice? How much life is six months? How bad can it get? Am I alone?
More informationLung cancer is not just one disease. There are two main types of lung cancer:
1. What is lung cancer? 2. How common is lung cancer? 3. What are the risk factors for lung cancer? 4. What are the signs and symptoms of lung cancer? 5. How is lung cancer diagnosed? 6. What are the available
More informationCellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
More informationTubular breast cancer
Tubular breast cancer This booklet is for people who would like more information about tubular breast cancer. It describes what tubular breast cancer is, its symptoms, how a diagnosis is made and the possible
More informationGENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW EFFICACY IN PEOPLE WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN LARGE PHASE III STUDY
NEWS RELEASE Media Contact: Tara Iannuccillo (650) 467-6800 Investor Contacts: Stefan Foser Karl Mahler (650) 467-2016 011 41 61 687 8503 GENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW
More informationPATHOLOGY. HercepTestTM. Product Information
PATHOLOGY HercepTestTM Product Information CLINICAL TRIALS HercepTest The First and Foremost Dako s pharmdx HercepTest was the first FDA-approved assay developed exclusively to aid physicians in identifying
More informationNew strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
More informationInflammatory Breast Cancer
Inflammatory Breast Cancer This document briefly describes inflammatory breast cancer. For more comprehensive information on this and other types of breast cancer, please refer to our document called Breast
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More informationActivity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationIn ELOQUENT-2, Empliciti was evaluated in patients who had received one to three prior
- First and only immunostimulatory antibody approved in the European Union for multiple myeloma - Accelerated assessment and approval based on long-term data from ELOQUENT-2, which evaluated Empliciti
More informationGuide to Understanding Breast Cancer
An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients
More informationRecruiting now. Could you help by joining this study?
Non-Small Cell Lung Cancer Recruiting now AstraZeneca is looking for men and women with locally advanced or metastatic non-small cell lung cancer (NSCLC) to join ATLANTIC, a clinical study to help investigate
More informationBreast cancer research and a changing treatment pathway
Breast cancer research and a changing treatment pathway Stuart McIntosh Clinical Senior Lecturer in Surgical Oncology, QUB Consultant Breast Surgeon, BCH What is the breast surgeon s role in 2016? Surgery
More informationGuide to Understanding. HER2-Positive Breast Cancer
Guide to Understanding HER2-Positive Breast Cancer Fill out our online survey today for a chance to win a $25 gift card! visit: surveymonkey.com/r/2016lbbc Tell us what you think of the Guide to Understanding
More informationTransgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO
Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous
More informationThe Impact of Taxotere on Adjuvant Breast Cancer
The Impact of Taxotere on Adjuvant Breast Cancer a report by Pierre Fumoleau and Henri Roché Centre Georges François Leclerc, Dijon, and Institut Claudius Regaud, Toulouse, France DOI: 10.17925/EOH.2005.0.0.1l
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationOne of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J.
Hormone Therapy in Postmenopausal Women With Breast Cancer * William J. Gradishar, MD ABSTRACT *Based on a presentation given by Dr Gradishar at a roundtable symposium held in Baltimore on June 28, 25.
More informationAbout breast cancer i
About breast cancer i About us Breast Cancer Network Australia (BCNA) is the peak organisation for all people affected by breast cancer in Australia. We provide a range of free resources, including the
More informationPatient Guide to Breast Cancer Surgery and Treatment
Patient Guide to Breast Cancer Surgery and Treatment Coree H. Flight attendant and mother of 3. Diagnosed with invasive breast cancer in 2009. An educational guide prepared by Genomic Health This Is Your
More informationManagement of Locally Advanced and Metastatic HER2-Positive Breast Cancer
Management of Locally Advanced and Metastatic HER2-Positive Breast Cancer Pretest Question #1 Which of the following is an antibody-drug conjugate indicated for use in HER2-positive metastatic breast cancer?
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Pertuzumab (Omnitarg/Perjeta ) for the first-line therapy of metastatic HER2 positive breast cancer DSD: Horizon Scanning in Oncology Nr. 31 ISSN online 2076-5940 Horizon
More informationGenetic Testing in Research & Healthcare
We Innovate Healthcare Genetic Testing in Research & Healthcare We Innovate Healthcare Genetic Testing in Research and Healthcare Human genetic testing is a growing science. It is used to study genes
More informationAn Introduction to PROSTATE CANCER
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
More informationInnovative people need room to breathe
92/93 Arthur D. Little How important is the protection of intellectual property to sustaining innovation in your business? Schwan Without patents there would be no innovation in our industry. Patents are
More informationBiomarker Trends in Breast Cancer Research
WHITE PAPER Biomarker Trends in Breast Cancer Research Jason Hill, PhD, Associate Director, External Science Affairs, Quintiles Quintiles examines the novel drug combinations and mechanisms of action that
More informationAvastin: Glossary of key terms
Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationBREAST CANCER WHAT HAPPENS AFTER SURGERY?
BREAST CANCER WHAT HAPPENS AFTER SURGERY? Contents: Planning further treatment Medical management of breast cancer Support and follow up Questions to ask your surgeon or oncologist Planning further treatment
More informationESMO 2014 Summary Breast Cancer
ESMO 2014 Summary Breast Cancer 1 7. 1 0. 2 0 1 4 A N NA D U R I G OVA M E D I C A L O N CO LO GY U N I V E R S I T Y H O S P I TA L S O F G E N E VA Outline 1. Early Breast Cancer Her2+ Neoadjuvant: Lapatax
More informationTheories on Metastasis: Innovative Thinking An Advocacy Perspective
Theories on Metastasis: Innovative Thinking An Advocacy Perspective Project LEAD Workshop NBCC Annual Advocacy Conference 2011 Musa Mayer AdvancedBC.org 1 The Big Question If we want to end death from
More informationRecommendation Strength Strong, supported by the evidence and expert consensus. Recommendation Benefit/Harm Evidence Quality
CHEMO- AND TARGETED THERAPY FOR WOMEN WITH HER2 NEGATIVE (OR UNKNOWN) ADVANCED BREAST Benefit/Harm Evidence Quality 1: Endocrine therapy, rather than chemotherapy, should be offered as the standard firstline
More informationUpdate on neoadjuvant treatment of breast cancer
Update on neoadjuvant treatment of breast cancer «IS PATHOLOGIC COMPLETE RESPONSE STILL A GOOD SURROGATE OF SURVIVAL?» Complete histological response varies according to tumoral type pcr (%) 40 35 30 25
More informationRoche Committed to innovation and profitable growth. Dr. Karl Mahler Head of Investor Relations. London, July 2011
Roche Committed to innovation and profitable growth Dr. Karl Mahler Head of Investor Relations London, July 2011 2 This presentation contains certain forward-looking statements. These forward-looking statements
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationInova. Breast Care Institute
Inova Breast Care Institute At the Inova Breast Care Institute, our commitment is to provide expert care for you, every step of the way. Our multidisciplinary team of more than 80 experts provides a full
More information